Security Snapshot

TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) Institutional Ownership

CUSIP: 88338N206

13F Institutional Holders and Ownership History from Q4 2021 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

47

Shares (Excl. Options)

3,930,452

Price

$2.02

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
TXMD on Nasdaq
Shares outstanding
11,676,558
Price per share
$2.07
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
3,930,452
Total reported value
$7,939,211
% of total 13F portfolios
0%
Share change
+520,174
Value change
+$1,050,571
Number of holders
47
Price from insider filings
$2.07
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Key facts

  • TXMD - TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 88338N206.
  • 47 institutions reported positions in Q1 2026.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 41 to 47 between Q4 2025 and Q1 2026.
  • Reported value moved from $5,517,397 to $7,939,211.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 47 institutions filings for Q1 2026.

Open SEC Evidence

Security key

88338N206

Latest holder period

Q1 2026

13F holders

47

13D/G owners

2

CIK / CUSIP context first

Open Q1 2026 holders TXMD full holder history TherapeuticsMD, Inc. SEC filings TherapeuticsMD, Inc. company facts TherapeuticsMD, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Significant Owners of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Clearline Capital LP 5.5% $705,096 635,222 Clearline Capital LP 31 Dec 2024
Baselake Partners, LP 5.2% $1,384,373 607,181 Baselake Partners, LP 30 Mar 2026

As of 31 Mar 2026, 47 institutional investors reported holding 3,930,452 shares of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD). This represents 34% of the company’s total 11,676,558 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) together control 34% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Rubric Capital Management LP 10% 1,192,191 0% 0.03% $2,408,226
Clearline Capital LP 5.4% 635,222 0% 0.1% $1,283,148
Squadron Capital Management LLC 3.6% 420,421 0.34% $849,250
VANGUARD CAPITAL MANAGEMENT LLC 3% 353,697 0% 0% $714,468
Tejara Capital Ltd 3% 345,852 -1.4% 0.23% $698,621
ADAR1 Capital Management, LLC 1.8% 209,210 0% 0.03% $422,604
RENAISSANCE TECHNOLOGIES LLC 1.3% 146,200 +52% 0% $295,324
MORGAN STANLEY 1.1% 129,217 0% 0% $261,018
BlackRock, Inc. 0.99% 115,145 -0.85% 0% $232,593
GEODE CAPITAL MANAGEMENT, LLC 0.94% 109,817 +3.5% 0% $221,884
CITADEL ADVISORS LLC 0.59% 68,314 +142% 0% $137,994
VANGUARD FIDUCIARY TRUST CO 0.55% 63,831 0% 0% $128,939
STATE STREET CORP 0.26% 30,100 0% 0% $60,802
XTX Topco Ltd 0.24% 27,487 0% $55,524
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.18% 21,220 -40% 0% $42,864
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.15% 17,000 0% 0% $34,340
NORTHERN TRUST CORP 0.14% 16,093 -2.2% 0% $32,508
DIMENSIONAL FUND ADVISORS LP 0.09% 10,706 0% $21,626
Cygnus Capital Advisors, LLC 0.08% 9,069 0.01% $18,000
Vanguard Global Advisers, LLC 0.04% 4,937 0% 0% $9,973
Tower Research Capital LLC (TRC) 0.01% 1,509 -39% 0% $3,048
NATIONAL BANK OF CANADA /FI/ 0.01% 610 0% 0% $1,226
Smartleaf Asset Management LLC 0.01% 601 0% 0% $1,196
UBS Group AG 0% 331 -70% 0% $669
JPMORGAN CHASE & CO 0% 293 0% 0% $583

Institutional Holders of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 3,930,452 $7,939,211 +$1,050,571 $2.02 47
2025 Q4 3,384,889 $5,517,397 +$146,413 $1.63 41
2025 Q3 3,303,788 $3,542,705 +$51,253 $1.08 43
2025 Q2 3,255,627 $3,776,528 -$96,760 $1.16 39
2025 Q1 3,343,589 $3,092,849 -$161,728 $0.92 39
2024 Q4 3,528,745 $3,034,778 +$127,744 $0.86 38
2024 Q3 3,379,026 $5,609,223 -$32,659 $1.66 34
2024 Q2 3,408,566 $5,487,879 -$167 $1.61 34
2024 Q1 3,377,053 $7,732,812 +$286,534 $2.29 43
2023 Q4 3,251,877 $7,316,577 -$358,133 $2.25 36
2023 Q3 2,987,555 $9,324,433 +$112,168 $3.02 36
2023 Q2 3,031,054 $12,488,021 -$296,992 $4.12 40
2023 Q1 3,115,140 $11,682,289 -$1,635,363 $3.75 38
2022 Q4 3,475,915 $19,431,091 +$6,039,029 $5.59 43
2022 Q3 2,070,807 $13,750,198 -$489,469 $6.64 29
2022 Q2 1,993,507 $19,835,726 +$19,831,622 $9.95 36
2022 Q1 10,800 $4,104 +$304 $0.38 2
2021 Q4 10,000 $3,555 $0.36 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .